Anti-toxin provider Jiangxi Institute joins biopharma IPO rush
The company enjoys a big share of China’s anti-tetanus market but is looking to diversify into antidotes for rabies and snake bites to drive future growth Key Takeaways: The company…
Recent Articles
RELATED ARTICLES
-
Ruanyun soars as China edtechs learn to live in new environment
RYET.US - Jiaxin mines Hong Kong, Kazakhstan for IPO funds
-
Singapore business dynasty has Vitasoy in its sights
0345.HK 0083.HK
- Shanghai family feud ties up $1 billion in property, offers lesson for investors
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- Mao Geping’s Hong Kong IPO gets lift from regulatory nod
-
Xiaocaiyuan sets the table for Hong Kong IPO. But is the timing right?
0999.HK
